Page 293 - medicina-integrativa_compress

CAPÍTULO 27 INSUFICIENCIA CARDÍACA 289

57. Spigset O: Reduced effect of warfarin caused by ubidecarenone 82. Mancini M, Rengo F, Lingetti M, et al: Controlled study on the
[Letter]. Lancet 344:1372-1373, 1994. therapeutic efficacy of propionyl-L-carnitine in patients with
58. Landbo C, Almdal TP: Interaction between warfarin and coenzyme Q 10 . congestive heart failure. Arzneimittelforschung 42:1101-1104, 1992.
Ugeskr Laeger 160:3226-3227, 1998. 83. Caponnetto S, Canale C, Masperone MA, et al: Efficacy of
59. Zhou Q, Zhou S, Chan E: Effect of coenzyme Q 10 on warfarin L-propionyl-carnitine treatment in patients with left ventricular
hydroxylation in rat and human liver microsomes. Curr Drug Metab dysfunction. Eur Heart J 15:1267-1273, 1994.
6:67-81, 2005. 84. Anand I, Chandrashekhan Y, De Giuli F, et al: Acute and chronic
60. Folkers K, Langsjoen P, Willis R, et al: Lovastatin decreases effects of propionyl-L-carnitine on the hemodynamics, exercise
coenzyme Q 10 levels in humans. Proc Natl Acad Sci U S A capacity, and hormones in patients with congestive heart failure.
87:8931-8934, 1990. Cardiovasc Drugs Ther 12:291-299, 1998.
61. Mortensen SA, Leth A, Agner E, et al: Dose-related decrease of serum 85. Rizos I: Three-year survival of patients with heart failure caused by
coenzyme Q 10 during treatment with HMG-CoA reductase inhibitors. dilated cardiomyopathy and L-carnitine administration. Am Heart J
Mol Aspects Med 18(Suppl):S137-S144, 1997. 139:S120-S123, 2000.
62. Ghirlanda G, Oradei A, Manto A, et al: Evidence of plasma CoQ 10 - 86. Anand I, Chandrashekhan Y, De Giuli F, et al: Study on propionyl-L-
lowering effect by HMG-CoA reductase inhibitors: A double-blind, carnitine in chronic heart failure. The Investigators of the Study on
placebo-controlled study. J Clin Pharmacol 3:226-229, 1993. Propionyl-L-Carnitine in Chronic Heart Failure. Eur Heart J 19:70-
63. Lamperti C, Naini AB, Lucchini V, et al: Muscle coenzyme Q 10 level 76, 1999.
in statin-related myopathy. Arch Neurol 62:1709-1712, 2005. 87. Arsenian MA: Carnitine and its derivatives in cardiovascular disease.
64. Langsjoen PH, Langsjoen AM: The clinical use of HMG CoA-reductase Prog Cardiovasc Dis 40:265-286, 1997.
inhibitors and the associated depletion of coenzyme Q 10 : A review of 88. Benvenga S, Amato A, Calvani M, Trimarchi F: Effects of carnitine
animal and human publications. Biofactors 18:101-111, 2003. on thyroid hormone action. Ann NY Acad Sci 1033:158-167, 2004.
65. Arsenian MA: Carnitine and its derivatives in cardiovascular disease. 89. Rector TS, Bank AJ, Mullen KA, et al: Randomized, double-blind,
Prog Cardiovasc Dis 40:265-286, 1997. placebo-controlled study of supplemental oral L-arginine in patients
66. Nakagawa T, Sunamori M, Suzuki A: The myocardial distribution with heart failure. Circulation 93:2135-2141, 1996.
and plasma concentration of carnitine in patients with mitral valve 90. Hambrecht R, Hilbrich L, Erbs S, et al: Correction of endothelial
disease. Surg Today 24:313-317, 1994. dysfunction in chronic heart failure: Additional effects of exercise
67. Pierpoint ME, Judd D, Goldenberg I, et al: Myocardial carnitine in training and oral L-arginine supplementation. J Am Coll Cardiol
end-stage congestive heart failure. Am J Cardiol 64:56-60, 1989. 35:706-713, 2000.
68. Suzuki Y, Masumura Y, Kobayashi A, et al: Myocardial carnitine 91. Lerman A, Burnett JC Jr, Higano ST, et al: Long-term L-arginine
deficiency in congestive heart failure. Lancet 1:116, 1982. supplementation improves small-vessel coronary endothelial
69. Regitz V, Shug AL, Fleck E: Defective myocardial metabolism in function in humans. Circulation 97:2123-2128, 1998.
congestive heart failure secondary to dilated cardiomyopathy and 92. Adams MR, McCredie R, Jessup W, et al: Oral L-arginine improves
coronary, hypertensive, and valvular heart disease. Am J Cardiol endothelium-dependent dilatation and reduces monocyte adhesion
65:755-760, 1990. to endothelial cells in young men with coronary artery disease.
70. Corr PB, Gross RW, Sobel BE: Amphipathic metabolites and membrane Atherosclerosis 129:261-269, 1997.
dysfunction in ischemic myocardium. Circ Res 55:135-154, 1984. 93. Bocchi EA, Vilella de Moraes AV, Esteves-Filho A, et al: L-Arginine
71. Shug AL, Subramanian R: Modulation of adenine nucleotide reduces heart rate and improves hemodynamics in severe congestive
translocase activity during myocardial ischemia. Z Kardiol 76(Suppl 5): heart failure. Clin Cardiol 23:205-210, 2000.
26-33, 1987. 94. Rector TS, Bank AJ, Mullen KA, et al: Randomized, double-blind,
72. Siliprandi N, Di Lisa F, Pivetta A, et al: Transport and function of placebo-controlled study of supplemental oral L-arginine in patients
L-carnitine and L-propionylcarnitine: Relevance to some with heart failure. Circulation 93:2135-2141, 1996.
cardiomyopathies and cardiac ischemia. Z Kardiol 76(Suppl 5):3-40, 95. Doutreleau S, Mettauer B, Piquard F, et al: Chronic but not acute oral
1987. L-arginine supplementation delays the ventilatory threshold during
73. Paulson DJ, Traxler J, Schmidt M, et al: Protection of the ischaemic exercise in heart failure patients. Can J Appl Physiol 30:419-432, 2005.
myocardium by L-propionyl-carnitine: Effects on the recovery of 96. Bednarz B, Jaxa-Chamiec T, Gebalska J, et al: L-Arginine
cardiac output after ischaemia and reperfusion, carnitine transport supplementation prolongs exercise capacity in congestive heart
and fatty acid oxidation. Cardiovasc Res 20:536-541, 1986. failure. Kardiol Pol 60:348-353, 2004.
74. Tassani V, Cattapan F, Magnanimi L, Peschechera A: Anaplerotic 97. Watanabe G, Tomiyama H, Doba N: Effects of oral administration
effect of propionyl carnitine in rat heart mitochondria. Biochem of L-arginine on renal function in patients with heart failure. J
Biophys Res Commun 199:949-953, 1994. Hypertens 18:229-234, 2000.
75. Di Lisa F, Menabo R, Siliprandi N: L-Propionyl-carnitine protection 98. McKevoy GK (ed): AHFS Drug Information. Bethesda, MD,
of mitochondria in ischemic rat hearts. Mol Cell Biochem 88: American Society of Health-System Pharmacists, 1998.
© Elsevier. Es una publicación MASSON. Fotocopiar sin autorización es un delito.
169-173, 1989. 99. Schulman SP, Becker LC, Kass DA, et al: L-Arginine therapy in acute
76. Ferrari R, Di Lisa F, de Jong JW, et al: Prolonged propionyl-L- myocardial infarction. JAMA 295:58-64, 2006.
carnitine pretreatment of rabbit: Biochemical, hemodynamic and 100. SOLVD Investigators: Effect of enalapril on survival in patients with
electrophysiological effects on myocardium. J Mol Cell Cardiol reduced left ventricular ejection fractions and congestive heart
24:219-232, 1992. failure. N Engl J Med 325:293-302, 1991.
77. Sethi R, Wang X, Ferrari R, Dhalla NS: Improvement of cardiac 101. The CONSENSUS Trial Study Group: Effects of enalapril on
function and beta-adrenergic signal transduction by propionyl mortality in severe congestive heart failure. N Engl J Med 316:
L-carnitine in congestive heart failure due to myocardial infarction. 1429-1435, 1987.
Coron Artery Dis 15:65-71, 2004. 102. Collaborative Group on ACE Inhibitor Trials: Overview of
78. Cherchi A, Lai C, Angelino F, et al: Effects of L-carnitine on exercise randomized trials of angiotensin-converting enzyme inhibitors on
tolerance in chronic stable angina: A multicenter, double-blind, mortality and morbidity in patients with heart failure. JAMA
randomized, placebo controlled crossover study. Int J Clin Pharmacol 273:1450-1456, 1995.
Ther Toxicol 23:569-572, 1985. 103. Carson PE: Rationale for the use of combination angiotensin-
79. Brevetti G, Chiariello M, Ferulano G, et al: Increases in walking converting enzyme inhibitor/angiotensin II receptor blocker therapy
distance in patients with peripheral vascular disease treated with in heart failure. Am Heart J 140:361-366, 2000.
L-carnitine: A double-blind, cross-over study. Circulation 77: 104. Pitt B, Poole-Wilson PA, Segal R, et al: Effects of losartan compared
767-783, 1988. with captopril on mortality in patients with symptomatic heart
80. Jeejeebhoy F, Keith M, Freeman M, et al: Nutritional failure: Randomized trial. The Losartan Heart Failure Survival Study
supplementation with MyoVive repletes essential cardiac myocyte ELITE II. Lancet 355:1582-1587, 2000.
nutrients and reduces left ventricular size in patients with left 105. McKelvie RS, Yusuf S, Pericak D, et al: Comparison of candesartan,
ventricular dysfunction. Am Heart J 143:1092-1000, 2002. enalapril, and their combination in congestive heart failure:
81. Ferrari R, Merli E, Cicchitelli G, et al: Therapeutic effects of Randomized Evaluation of Strategies for Left Ventricular
L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a Dysfunction (RESOLVD) pilot study. Circulation 100:1056-1064,
review. Ann NY Acad Sci 1033:79-91, 2004. 1999.